Immunomodulating effect of inositol hexaphosphate against Aeromonas hydrophila-endotoxin.
The present study was carried out to evaluate the effect of inositol hexaphosphate (IP6) administration on endotoxemia as an example of the systemic inflammatory response. Mice were divided into three groups as follows: First group, remained as a naive group injected intraperitoneally (i.p.) with PBS (pH 7.4; 0.2 ml/mice) at intervals parallel to the treated groups. The second group was injected i.p. with the lipopolysaccharide (LPS) of Aeromonas hydrophila once a week for four weeks at a dose of LPS suspension: 20 mg/kg mice/week. The third group was injected with the same LPS dose and synergistically intubated with IP6 three times a week for four weeks at a total dose of 4 0mg/kg. At different experimental periods (1, 2, 3 and 4 weeks), six animals from each group were sacrificed under mild diethyl ether anesthesia. Blood and sera were taken for the estimation of phagocytic activity, electrophoretic pattern of proteins and immunoglobulin levels. Also, a slice of liver was homogenized to estimate the respiratory burst enzymes activities and nitric acid synthesis. Histopathological changes of hepatic tissues were investigated. In the LPS-treated group, marked increase in the phagocytic activities and nitric oxide synthesis, and a decrease in hepatocyte catalase, total peroxidase and superoxide dismutase activities were observed. The histopathological features revealed a degeneration and highly mitotic division within the hepatic nuclei in addition to some karyomegaly and nuclear pyknosis. During the treatment period, liver sections of the LPS+IP6 group showed somewhat regenerative features. Reduction in the toxicity of free radicals by IP6 was observed and the IP6 effect seemed to be responsible for the observed ameliorative influence.
Abu-El-Saad
Abdel-Aziz S A
AA
Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
D016980:Aeromonas hydrophila / Q000276:immunology* / Q000472:pathogenicity; D000818:Animals; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors*; D004768:Enterotoxins / Q000037:antagonists & inhibitors*; D007155:Immunologic Factors / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D007958:Leukocyte Count; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008297:Male; D051379:Mice; D010833:Phytic Acid / Q000494:pharmacology*
D001426:Bacterial Proteins; D004768:Enterotoxins; D007155:Immunologic Factors; D008070:Lipopolysaccharides; C082174:cytolytic enterotoxin protein, Aeromonas; D010833:Phytic Acid